CSRC approves Tainomab's registration for the Sci-Tech Innovation Board IPO.

On June 4th, the China Securities Regulatory Commission issued a reply approving Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd.'s initial public offering of stocks. It is reported that Tainuo Maibo plans to list on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with Huatai United Securities as its sponsoring institution and plans to raise 1.5 billion yuan. According to the prospectus, the company was established in 2015 and is an innovative biopharmaceutical company dedicated to blood product replacement therapy for the global market. Its core product, Staduta monoclonal antibody injection (also known as "recombinant anti-tetanus toxin human monoclonal antibody TNM002", trade name: Xintituo, hereinafter referred to as "Staduta monoclonal antibody injection" or "TNM002"), was approved for listing in China in February 2025, making it the world's first recombinant antibody drug against tetanus toxin, recognized by China's CDE as a breakthrough therapy and included in the priority review process (also the first domestically innovative biopharmaceutical drug in the field of anti-infection to be identified as a breakthrough therapy), and granted Fast Track status by the US FDA, signifying revolutionary significance in the field of tetanus prevention worldwide. Another core product of the company, recombinant anti-respiratory syncytial virus human monoclonal antibody TNM001 (hereinafter referred to as "TNM001"), has been submitted for NDA for approval in non-high-risk and high-risk infant populations and has also been included in the priority review process. After years of accumulation, the company has established core technology platforms with independent intellectual property rights, such as the "high-throughput human monoclonal antibody R&D comprehensive technology platform HitmAb," "high-efficiency antibody expression CHO-GS cell platform," "process development platform," "biological analysis platform," etc., continuously cultivating and improving innovative core technology capabilities in key drug research and industrialization processes such as drug discovery, engineered cell line construction, process and quality development, pharmacological research, toxicological research, pharmacokinetic research, clinical development, and large-scale production in compliance with international GMP standards.